Trials / Withdrawn
WithdrawnNCT06332300
An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC
An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Lateral Ventricular Chemotherapy in Patients With Non-squamous NSCLC With Soft Meningeal Metastases Who Have Failed EGFR-TKI Therapy
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Jiangsu Province Nanjing Brain Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study was a single-arm design to explore the efficacy and safety of Adebelimumab in combination with famitinib and lateral ventricular chemotherapy in patients with floppy meningeal metastases from non-squamous NSCLC who have failed EGFR-TKI therapy, and included patients with pathologically confirmed non-squamous non-small cell lung cancer.
Detailed description
Despite the rapid progress of immune-combination therapy in lung cancer, immune-combination anti-vascular regimens after EGFR-TKI failure have not been explored in NSCLC LM, and further exploration of superior regimens targeting brain metastases is needed. Therefore, we plan to conduct an exploratory clinical study of adebenosumab in combination with famitinib and lateral ventricular chemotherapy in patients with non-squamous NSCLC with soft meningeal metastases who have failed EGFR-TKI therapy, with the aim of providing a more feasible and effective comprehensive treatment strategy for this group of patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adebelimumab+Famitinib + FOLFIRI+Ariely | Adebelimumab in combination with famitinib and lateral ventricular chemotherapy in patients with non-squamous NSCLC with soft meningeal metastases who have failed EGFR-TKI therapy |
Timeline
- Start date
- 2024-02-01
- Primary completion
- 2025-02-01
- Completion
- 2026-02-01
- First posted
- 2024-03-27
- Last updated
- 2024-08-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06332300. Inclusion in this directory is not an endorsement.